New data from landmark helios-b phase 3 study presented at esc congress 2025 demonstrate vutrisiran's long-term cardiovascular benefit in attr-cm

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced results of new analyses from the helios-b phase 3 study of amvuttra® (vutrisiran), an rnai therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (attr-cm) in adults. data from the 12-month follow-up of the ongoing open-label extension (ole) period of helios-b were presented during an oral sess.
ALNY Ratings Summary
ALNY Quant Ranking